WebSep 23, 2016 · The subsequent intracellular signaling pathway analysis indicated that pAkt and p62 expression levels correlated with alterations in the IC50 values for cisplatin in ovarian cancer, providing an... WebApr 11, 2024 · The poster shows the final data from a phase 2 study evaluating the ability of the DRP ® companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that...
New combination chemotherapy of cisplatin with an …
WebMar 1, 2024 · Cisplatin is a platinum containing compound used for the treatment of different types of cancers. Quantitative determination of cisplatin has been carried out … WebOct 25, 2016 · The MTT assay is currently the most extensively used method for IC50 measurements. Here, we dissected the critical reasons behind MTT-dependent IC50 … portman lights gdynia
Frontiers Overcoming Limitations of Cisplatin Therapy by …
After observing the enhanced cell-killing efficacy of the combination of CDDP and BV10 in various cancer cell lines and studying cell death processes, we further investigated the anti-cancer effect of this combination in the xenograft mouse models of lung, ovarian and cervical cancers. The typical dose of … See more The results of the effect of the combination of CDDP with BV10 on in vitro cell viability and clonogenic death are shown in Fig. 3. Figure 3A shows the … See more To demonstrate the DET mechanism of the combination, we made real-time measurements of the reaction between CDDP and BV10 … See more Figure 4A shows representative images of HeLa cells treated by CDDP with/without the combination with BV10 for 12 h, where apoptotic cells were … See more WebFeb 15, 2024 · We found that cisplatin response in model HNSCC cancer cells was modified by coculture with CAFs, was CAF-specific, and different patient-derived CAFs had a different "sensitizing ratio". Increased expression of VEGFA, PGE2S, COX2, EGFR, and NANOG in cancer cells was characteristic for the increase of resistance. WebAbstract Cisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. ... Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer and incubated with anti-USP14 (ab70311; Abcam), anti-EGFR (ab52894; Abcam), or normal IgG (sc-2027; Santa Cruz ... optionalpha trading calender